Abstract

ObjectivesThis study aims to evaluate the value of machine learning-based dynamic contrast-enhanced MRI (DCE-MRI) radiomics nomogram in prediction treatment response of neoadjuvant chemotherapy (NAC) in patients with osteosarcoma.MethodsA total of 102 patients with osteosarcoma and who underwent NAC were enrolled in this study. All patients received a DCE-MRI scan before NAC. The Response Evaluation Criteria in Solid Tumors was used as the standard to evaluate the NAC response with complete remission and partial remission in the effective group, stable disease, and progressive disease in the ineffective group. The following semi-quantitative parameters of DCE-MRI were calculated: early dynamic enhancement wash-in slope (Slope), time to peak (TTP), and enhancement rate (R). The acquired data is randomly divided into 70% for training and 30% for testing. Variance threshold, univariate feature selection, and least absolute shrinkage and selection operator were used to select the optimal features. Three classifiers (K-nearest neighbor, KNN; support vector machine, SVM; and logistic regression, LR) were implemented for model establishment. The performance of different classifiers and conventional semi-quantitative parameters was evaluated by confusion matrix and receiver operating characteristic curves. Furthermore, clinically relevant risk factors including age, tumor size and site, pathological fracture, and surgical staging were collected to evaluate their predictive values for the efficacy of NAC. The selected clinical features and imaging features were combined to establish the model and the nomogram, and then the predictive efficacy was evaluated.ResultsThe clinical relevance risk factor analysis demonstrates that only surgical stage was an independent predictor of NAC. A total of seven radiomic features were selected, and three machine learning models (KNN, SVM, and LR) were established based on such features. The prediction accuracy (ACC) of these three models was 0.89, 0.84, and 0.84, respectively. The area under the subject curve (AUC) of these three models was 0.86, 0.92, and 0.93, respectively. As for Slope, TTP, and R parameters, the prediction ACC was 0.91, 0.89, and 0.81, respectively, while the AUC was 0.87, 0.85, and 0.83, respectively. In both the training and testing sets, the ACC and AUC of the combined model were higher than those of the radiomics models (ACC = 0.91 and AUC = 0.95), which indicate an outstanding performance of our proposed model.ConclusionsThe radiomics nomogram demonstrates satisfactory predictive results for the treatment response of patients with osteosarcoma before NAC. This finding may provide a new decision basis to improve the treatment plan.

Highlights

  • Osteosarcoma is the most common primary malignant bone tumor, accounting for approximately 12% of primary bone tumors and mostly occurring in adolescents with a high degree of malignancy

  • The patient inclusion criteria were as follows: [1] osteosarcoma confirmed by histopathology, [2] MRI scans performed at two timepoints, and [3] more than two cycles of neoadjuvant chemotherapy (NAC) treatment were performed in the local hospital

  • There was a total of 102 patients with osteosarcoma (60 males and 42 females; mean age: 17 ± 9.77 years; range: 5–57 years), where 71 cases belong to the effective group and 31 cases belong to the ineffective group

Read more

Summary

Introduction

Osteosarcoma is the most common primary malignant bone tumor, accounting for approximately 12% of primary bone tumors and mostly occurring in adolescents with a high degree of malignancy. A natural prognosis of osteosarcoma is extremely difficult. The 5-year survival rate of patients undergoing surgery alone was only 20–30% [1], and its diagnosis, treatment, and prognosis have been the research focus. With neoadjuvant chemotherapy (NAC), the 5-year survival rate improved to 60–80%, and the overall limb salvage rate increased from 10–20 to 80–90% [2]. NAC is the most critical prognostic factor for osteosarcoma; except for operation, it can significantly extend the progression-free survival and improve life quality [3]. The response to NAC has a direct influence on the formulation of the clinical treatment protocols. Effective evaluation of the efficacy of NAC is critical [4]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call